Zucara Therapeutics Successfully Completes Single and Multiple Ascending Dose Phase 1 Trial of ZT-01

May 26, 2021 by zucaraadmin

Zucara Therapeutics Successfully Completes Single and Multiple Ascending Dose Phase 1 Trial of ZT-01 Toronto, Canada, May 26, 2021 –

Zucara Therapeutics Expands ZT-01 Development Program to Type 2 Diabetes

November 2, 2020 by zucaraadmin

Zucara Therapeutics Expands ZT-01 Development Program to Type 2 Diabetes – ZT-01 Development for T2D to be Supported by Nearly

September 29, 2020 by zucaraadmin

Zucara Therapeutics Doses First Subject in Phase 1 Trial of ZT-01 – Phase 1 Trial to Evaluate ZT-01 for the

March 31, 2020 by zucaraadmin

Zucara Therapeutics Announces US$21 Million Series A Financing – Proceeds to Fund Development of ZT-01 Through Phase 2 Clinical Trials

September 19, 2019 by zucaraadmin

Dr. Richard Liggins, Chief Scientific Officer, presenting at EASD in Barcelona. TORONTO, Canada and BARCELONA, Spain: Zucara Therapeutics Inc., a

July 12, 2019 by zucaraadmin

Toronto & Vancouver, Canada: Zucara Therapeutics Inc., a life sciences company developing the first once-daily therapeutic to prevent hypoglycemia in

June 24, 2019 by zucaraadmin

(Michael Midmer & Dr. Mladen Vranic) Dr. Mladen Vranic, a leading scientist and advocate for the advancement of diabetes research,

May 14, 2019 by zucaraadmin

TORONTO, Canada: Zucara Therapeutics Inc., a life sciences company developing the first once-daily therapeutic to prevent hypoglycemia in people with

March 13, 2019 by zucaraadmin

Zucara Therapeutics Inc., a life sciences company developing the first once-daily therapeutic to prevent hypoglycemia in people with Type 1

November 14, 2018 by zucaraadmin

Typically occurring overnight, hypoglycemia puts over 8 million people with diabetes at fatal risk during their sleep. Current therapies offer